Medexus Pharmaceuticals (TSE:MDP) Price Target Raised to C$4.50 at Stifel Nicolaus

Medexus Pharmaceuticals (TSE:MDP) had its price target hoisted by Stifel Nicolaus from C$4.15 to C$4.50 in a research note published on Tuesday,BayStreet.CA reports.

Several other brokerages have also recently issued reports on MDP. Leede Financial set a C$8.25 target price on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a report on Monday, September 30th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Finally, Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Medexus Pharmaceuticals currently has an average rating of “Strong Buy” and an average price target of C$5.58.

Medexus Pharmaceuticals Stock Up 5.2 %

Shares of TSE MDP opened at C$4.47 on Tuesday. The firm’s 50-day moving average price is C$2.88 and its 200-day moving average price is C$2.59. Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$4.50. The company has a market cap of C$109.65 million, a PE ratio of 89.40 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.